Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • biosimlar

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Roche receives FDA clearance for whooping cough test

    There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Sandoz launches first and only multiple sclerosis biosimilar in US

    The treatment is FDA-approved to treat MS and Crohn’s disease

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Genentech announces positive clinical results for BTK inhibitor MS treatment

    Multiple sclerosis affects more than 2.9 million people globally

    - PMLiVE

    Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

    Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    - PMLiVE

    Novartis to acquire Avidity Biosciences in deal worth $12bn

    The acquisition will expand Novartis’ neuroscience pipeline

    - PMLiVE

    Roche’s small cell lung cancer therapy approved by FDA

    This is the first and only approved combination therapy for extensive-stage small cell lung cancer

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links